NFJ Investment Group LLC Invests $7.76 Million in West Pharmaceutical Services, Inc. $WST

NFJ Investment Group LLC purchased a new position in West Pharmaceutical Services, Inc. (NYSE:WST) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 21,614 shares of the medical instruments supplier’s stock, valued at approximately $7,759,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wealth Alliance LLC increased its position in West Pharmaceutical Services by 3.8% in the first quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock worth $237,000 after buying an additional 35 shares during the period. IFM Investors Pty Ltd grew its position in shares of West Pharmaceutical Services by 0.3% during the first quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock worth $3,452,000 after acquiring an additional 43 shares during the last quarter. Compound Planning Inc. grew its position in shares of West Pharmaceutical Services by 3.6% during the first quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier’s stock worth $307,000 after acquiring an additional 43 shares during the last quarter. Aptus Capital Advisors LLC increased its holdings in shares of West Pharmaceutical Services by 5.5% in the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock worth $249,000 after acquiring an additional 47 shares during the period. Finally, Cornerstone Planning Group LLC increased its holdings in shares of West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 50 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

WST has been the subject of a number of analyst reports. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Stephens restated an “overweight” rating and issued a $360.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Wolfe Research initiated coverage on West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective for the company. Finally, BNP Paribas Exane initiated coverage on West Pharmaceutical Services in a report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $368.08.

West Pharmaceutical Services Stock Performance

WST stock opened at $354.53 on Friday. The company has a 50-day simple moving average of $348.11 and a 200 day simple moving average of $299.38. The company has a market capitalization of $24.95 billion, a P/E ratio of 45.39, a PEG ratio of 2.47 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. During the same quarter last year, the company earned $1.84 EPS. West Pharmaceutical Services’s quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.